Highest-materiality recent filing
Phase 2 CALMA trial for IGC-AD1 in agitation in Alzheimer's: >80% of 146 target participants completed dosing.
IGC Pharma raises $514K via two convertible promissory notes with OID
FirstFire note: $346,910 principal at $307K purchase price, OID $39,910, 12% interest, matures April 10, 2027.
IGC Pharma increases authorized common stock from 150M to 600M shares
Amendment effective Dec 12, 2025, after stockholder approval on Oct 10, 2025.
IGC Pharma shareholders approve 4x increase in authorized shares to 600M and 5M share grant
Shareholders approved amendment to increase authorized common stock from 150M to 600M shares.
IGC Pharma subsidiary sells assets and facility to Wellness Essentials for ~$2.7M
Holi Hemp sold equipment, inventory, and Vancouver ready-to-move facility to Wellness Essentials Northwest.
IGC Pharma Phase 2 CALMA trial shows significant agitation reduction in Alzheimer's patients
Phase 2 interim: CMAI total score improvement -10.46 at week 6 (p=0.042, Cohen d=0.79) vs placebo.
IGC Pharma reports positive interim Phase 2 results for IGC-AD1 in Alzheimer's agitation
Cohen's d effect size at week 6=0.66, CMAI LS mean difference vs placebo=-10.45, p=0.037.
IGC Pharma appoints Terry Lierman as independent director to advance Alzheimer's pipeline
Terry Lierman appointed as independent Class B director, effective March 12, 2024.
IGC Pharma enters $60M ATM equity offering with A.G.P./Alliance Global Partners
On Oct 27, 2023, IGC Pharma entered an ATM sales agreement with A.G.P./Alliance Global Partners to sell up to $60M of common stock.
IGC Pharma raises $3M in private placement of 10M shares at $0.30/sh
Gross proceeds of $3M from Bradbury Asset Management (≈$2B AUM) and three other investors.
IGC receives U.S. patent (#11,351,152) for CBD-based seizure disorder treatment
Patent covers compositions combining CBD with other compounds to treat seizure disorders and epilepsy in humans and animals.
IGC enters 5-year CEO employment agreement with Ram Mukunda; salary $360K
Employment agreement effective November 18, 2021; initial 5-year term with automatic 12-month renewals.
On March 12, 2024, the Board of Directors (the “Board”) of IGC Pharma, Inc. (the “Company” or “IGC”) appointed Mr. Terry Lierman (“Mr. Lierman”) to serve on the Board as a Class B director.
On December 24, 2022, John E. Lynch, a Director of India Globalization Capital Inc. (the “Company” or “IGC”), passed away.
On September 9, 2022, Ram Mukunda and Congressman James Moran were elected to India Globalization Capital’s (the “Company”) Board of Directors at the 2022 Annual Meeting of Stockholders (the “Annual Meeting”), to serve as Class C directors, until the 2025 annual meeting of stockholders
and Ms. Claudia Grimaldi was elected to the Company’s Board of Directors at the Annual Meeting, to serve as a Class A director, until the 2023 annual meeting of stockholders
On September 9, 2022, Ram Mukunda and Congressman James Moran were elected to India Globalization Capital’s (the “Company”) Board of Directors at the 2022 Annual Meeting of Stockholders (the “Annual Meeting”), to serve as Class C directors, until the 2025 annual meeting of stockholders
On March 23, 2022, the Board of Directors (the “Board”) of India Globalization Capital Inc. (the “Company” “IGC” or “we”) appointed Ms. Claudia Grimaldi (“Ms. Grimaldi”) to serve on the Board as a non-independent director.
On January 18, 2022, the Board of Directors (the “Board”) of India Globalization Capital Inc. (the “Company” or “IGC”) appointed former Congressman Jim Moran (“Congressman Moran”) to serve on the Board as a Class C director.
On October 15, 2021, Richard Prins was elected to India Globalization Capital’s (the “Company”) Board of Directors at the Annual Meeting, to serve as a Class B director
Max materiality 0.85 · Median 0.55 · Most common event other_material